Capmatinib
- Generic Name
- Capmatinib
- Brand Names
- Tabrecta
- Drug Type
- Small Molecule
- Chemical Formula
- C23H17FN6O
- CAS Number
- 1029712-80-8
- Unique Ingredient Identifier
- TY34L4F9OZ
- Background
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
- Indication
用于治疗局部晚期或转移性MET外显子14跳跃（METEX 14）突变的非小细胞肺癌（NSCLC）患者。
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03647488
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03040973
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT02795429
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 1
- Registration Number
- NCT02587650
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 373
- Registration Number
- NCT02414139
- Locations
- 🇺🇸
University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center, Orange, California, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
🇺🇸Pacific Shores Medical Group SC, Long Beach, California, United States
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02335944
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
🇺🇸Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.